Alkem Labs gets USFDA EIR for St Louis facility in US

Published On 2020-05-15 05:43 GMT   |   Update On 2020-05-15 05:43 GMT
Advertisement

New Delhi: Drug firm Alkem Laboratories on Tuesday said the US health regulator has issued an establishment inspection report (EIR) for its St Louis facility in the US.

The United States Food and Drug Administration (USFDA) has issued an EIR for the St Louis plant and the inspection has now been closed by the regulator, Alkem Laboratories said in a filing to the BSE.

The inspection was conducted by the USFDA from January 27, 2020, to February 6, 2020, it had said in an earlier filing.

Advertisement

At the end of the inspection, the company had received Form 483 with three observations and had said it shall submit to the USFDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection.

Shares of Alkem Laboratories were trading at Rs 2,576.60 per scrip on the BSE, down 0.88 per cent from the previous close.

Alkem Laboratories is a multinational pharmaceutical company headquartered in Mumbai.

The Company manufactures and sells pharmaceutical generics, formulations and neutraceutricals in India.

Read also: Lupin receives USFDA EIR for Vizag API Facility


Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News